oxazepam has been researched along with Chronic Disease in 8 studies
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.
oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatic drug metabolism was examined in patients with chronic pancreatitis and healthy controls by using a cocktail design with three different model compounds: antipyrine to express phase-I oxidation, oxazepam to express phase-II conjugation, and indocyanine green (ICG), a high-clearance compound." | 9.09 | Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ( Andersen, V; Larsen, S; Sonne, J, 1999) |
| " Oxazepam and flurazepam were effective in improving some polysomnographically defined measures of nocturnal sleep in 14 patients with chronic insomnia; flurazepam produced substantial daytime sleepiness and oxazepam did not." | 9.05 | Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. ( Bliwise, D; Dement, W; Greenblatt, DJ; Seidel, W, 1984) |
| "Hepatic drug metabolism was examined in patients with chronic pancreatitis and healthy controls by using a cocktail design with three different model compounds: antipyrine to express phase-I oxidation, oxazepam to express phase-II conjugation, and indocyanine green (ICG), a high-clearance compound." | 5.09 | Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ( Andersen, V; Larsen, S; Sonne, J, 1999) |
| " Oxazepam and flurazepam were effective in improving some polysomnographically defined measures of nocturnal sleep in 14 patients with chronic insomnia; flurazepam produced substantial daytime sleepiness and oxazepam did not." | 5.05 | Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. ( Bliwise, D; Dement, W; Greenblatt, DJ; Seidel, W, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conell, LJ | 1 |
| Berlin, RM | 1 |
| Bliwise, D | 1 |
| Seidel, W | 1 |
| Greenblatt, DJ | 1 |
| Dement, W | 1 |
| Perney, P | 1 |
| Butterworth, RF | 1 |
| Mousseau, DD | 1 |
| Lavoie, J | 1 |
| Fabbro-Peray, P | 1 |
| Blanc, F | 1 |
| Layrargues, GP | 1 |
| Andersen, V | 1 |
| Sonne, J | 1 |
| Larsen, S | 1 |
| Geiselmann, B | 1 |
| Kastner, W | 1 |
| Hirsch, W | 1 |
| Schildwächter, G | 1 |
| Böhlau, V | 1 |
2 trials available for oxazepam and Chronic Disease
| Article | Year |
|---|---|
Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia.
Topics: Chronic Disease; Circadian Rhythm; Electroencephalography; Electromyography; Electrooculography; Flu | 1984 |
Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Chronic Disease; Coloring Agents; Female | 1999 |
6 other studies available for oxazepam and Chronic Disease
| Article | Year |
|---|---|
Withdrawal after substitution of a short-acting for a long-acting benzodiazepine.
Topics: Anti-Anxiety Agents; Anxiety; Chronic Disease; Delayed-Action Preparations; Diazepam; Flurazepam; Ha | 1983 |
Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake.
Topics: Animals; Benzodiazepines; Binding, Competitive; Cell Fractionation; Cerebellum; Chronic Disease; Clo | 1998 |
Informed refusal: the patient's influence on long-term treatment.
Topics: Altruism; Antipsychotic Agents; Beneficence; Chronic Disease; Decision Making; Disclosure; Ethics, M | 1994 |
[Effect of oxazepam (Adumbran) on intraocular pressure during long-term medication].
Topics: Chronic Disease; Drug Evaluation; Female; Glaucoma; Humans; Intraocular Pressure; Male; Oxazepam; Ti | 1974 |
[Therapy of psychogenic concomitant symptoms in patients with liver diseases].
Topics: Affective Symptoms; Chronic Disease; Female; Hepatitis; Humans; Liver Diseases; Male; Oxazepam; Psyc | 1973 |
[Results of the Tranquo-Alupent test in patients with chronic asthmatoid bronchitis].
Topics: Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease; Humans; Metaproterenol; Oxazepam; Phenet | 1969 |